Received Aug 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | — | — |
patient was given Menveo at age 10 and 1 year later it was given a second dose of Menveo.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 11-year-old female patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. Previously administered products included Menveo (at age of 10 years). On an unknown date, the patient received the 2nd dose of Menveo. On an unknown date, an unknown time after receiving Menveo, the patient experienced extra dose administered (Verbatim: patient was given Menveo at age 10 and 1 year later it was given a second dose of Menveo.). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 29-JUL-2025 Pharmacist explained that a patient was given Menveo at age 10 and 1 year later it was given a second dose of Menveo, which led to extra dose administered. The reporter did not have patient initials or date of birth and they did not have dates of administration, lot number or expiration dates for any of the 2 vaccines. The reporter declined consent to follow up with Safety Team. Did not consent to follow-up.